Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study
This single-centre retrospective study (n=2877; 850 with hypertension) found mortality in patients with Covid-19 was similar for those receiving RAAS inhibitors vs those receiving other antihypertensives (2.2% v 3.6%; adjusted HR 0.85; 95% CI 0.28-2.58; p=0.774).
Source:
European Heart Journal
SPS commentary:
A related editorial notes this study shows patients taking RAAS inhibitors were not exposed to a higher risk of mortality. Several papers have demonstrated similar results, with experts advising that ACEIs and ARBs not be discontinued in patients infected with SARS-CoV2. Clinical trials testing the safety and efficacy of RAAS blockers in Covid-19 patients are underway.